Injunction Barring Drug Sales Vacated By Federal Circuit, New Trial Ordered

(October 6, 2017, 12:34 PM EDT) -- WASHINGTON, D.C. — A Delaware federal judge erred by excluding priority date evidence and by instructing jurors that written description can be satisfied by the disclosure of a newly characterized antigen, the Federal Circuit U.S. Court of Appeals ruled Oct. 5 in a patent dispute over the cholesterol drug Repatha, which features the active ingredient “evolocumab” (Amgen Inc., et al., v. Sanofi, et al., No. 17-1480, Fed. Cir., 2017 U.S. App. LEXIS 19416)....

Attached Documents

Related Sections